In the OCEANIC-AF trial, asundexian resulted in a small increase in the rates of stroke and lowered bleeding compared with apixaban in patients with atrial fibrillation (AF) who were naive to oral ...

Despite secondary prevention with oral anticoagulation (OAC), the risk for recurrent ischemic stroke (IS) and mortality is high in patients with atrial fibrillation (AF). However, OAC discontinuation ...

Discontinuing oral anticoagulation (OAC) therapy resulted in a lower risk of a composite of stroke, systemic embolism or major bleeding than continuing OAC therapy in patients who had successful ...

For patients who require chronic oral anticoagulation (OAC)—mostly for A-fib—and who undergo TAVR, adding 3 months of clopidogrel to the antithrombotic regimen after the procedure does not appear to ...